A New Vaccine Free of Side Effects
Studies of a new split vaccine Microsplit developed at Immunopreparat are ongoing. Preclinical studies have already been completed, and first phase clinical studies are starting.
This vaccine is remarkable as it contains not only surface but also inner antigens, inducing cross immunity against a few strains of influenza virus.
The vaccine will protect against new strains of influenza type A virus. The vaccine is free of lipid components, and does not induce side effects. It is therefore well-tolerated by patients.